In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • MRI-guided Stereotactic Laser Ablation of Presumed Cavernous Malformations in Drug-resistant Epilepsy

    Final Number:
    140

    Authors:
    D. Jay McCracken MD; Robert E. Gross MD PhD; Jon Timothy Willie MD PhD; David Lozada MD

    Study Design:
    Other

    Subject Category:
    Functional Neurosurgery

    Meeting: 2014 ASSFN Biennial Meeting

    Introduction: Open surgical resection is generally indicated for symptomatic cavernous malformations, including those associated with medically refractory epilepsy. Minimally invasive alternatives may maintain therapeutic efficacy while minimizing complications and disfigurement. MRI-guided stereotactic laser ablation (SLA) is a novel, FDA-cleared, minimally invasive approach to treating lesional epilepsy and brain tumors, including deep-seated lesions. To date, this approach has not been reported for cavernous malformations (CM). We present a case series of SLA of presumed CM causing refractory epilepsy.

    Methods: Five patients with medically refractory epilepsy undergoing standard presurgical evaluation (3-Tesla MRI, fluoro-deoxyglucose PET, neuropsychological evaluation, and inpatient video-EEG studies) were found to have corresponding lesions consistent with CM. Each underwent stereotactic placement of a laser fiber assembly (optical fiber in a saline-cooled 1.6-mm diameter catheter, Visualase, Inc.) via twist drill hole under general anesthesia. Real-time MR anatomic and thermal imaging verified placement and extent of ablation of CM and surrounding cortical rim during ablation with a 15W diode laser.

    Results: MR imaging revealed no evidence of hemorrhage following fiber placement within presumed CM. Immediate post-procedure contrasted imaging confirmed ablation in all cases. We detected no adverse events or neurological deficits. No ICU admissions were indicated and patients were discharged the following day. Three patients with temporal lobe lesions are seizure free at 6-15 months follow-up. One patient with a frontal lobe lesion has had a significant reduction in seizure frequency and severity, but is not seizure-free. It is too soon for seizure follow-up on the most recent patient.

    Conclusions: Minimally invasive MRI-guided SLA of presumed epileptogenic CM is a potentially safe and effective alternative to open resection. We have performed this procedure without complication in five patients who have experienced excellent seizure outcomes. With additional experience this technique may become an excellent first option for patients with this disorder.

    Patient Care: By providing a minimally invasive alternative to treating drug-resistant epilepsy secondary to cavernous malformations, patients will experience shorter hospital stays and complications. The initial results show a favorable reduction in seizure frequency and intensity, if not complete cessation, compared to open resection. With more experience, this could become an excellent first option to treating patients with this disease and reserving open resection for patients who fail to achieve their desired outcome with the initial procedure.

    Learning Objectives: By the end of the presentation, participants should be able to: 1) Describe the natural history and classical treatment of cavernoma related drug-resistant epilepsy 2) Describe the technique for minimally invasive stereotactic laser ablation of cavernous malformations 3) Understand the potential benefits, risks, and complications associated with the new procedure

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy